Immucell (ICCC)

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics.

Company profile

Ticker

ICCC

Exchange

NASDAQ

Website

www.immucell.com

CEO

Michael Brigham

Incorporated

Delaware

Location

Maine

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • QuidelOrtho • Meridian Bioscience • Celldex Therapeutics • Achieve Life Sciences ...

SEC CIK

0000811641

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

IRS number

10382980

ICCC stock data

1M 1Y 5Y

News

From Benzinga Pro

ImmuCell Q2 EPS $(0.09) Down From $0.02 YoY, Sales $3.86M Down From $4.54M YoY

11 Aug 22

ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.09) per share. This is a 550 percent decrease over earnings of $0.02 per share from the same period last year. The company reported $3.86 million in sales this

Earnings Scheduled For August 11, 2022

11 Aug 22

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Press releases

From Benzinga Pro

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022

11 Aug 22

PORTLAND, Maine, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

4 Aug 22

PORTLAND, Maine, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and

ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®

27 Jul 22

PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and

ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

7 Jul 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart ICCC financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.04M	11.04M	11.04M	11.04M	11.04M	11.04M
Cash burn (monthly)	257.97K	(no burn)	227.67K	(no burn)	(no burn)	(no burn)
Cash used (since last report)	369.47K	n/a	326.07K	n/a	n/a	n/a
Cash remaining	10.67M	n/a	10.72M	n/a	n/a	n/a
Runway (months of cash)	41.4	n/a	47.1	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Immucell earnings reports.

Recent insider trades

ICCC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	8.25	400	3.3K	94,019
14 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	8.05	50	402.5	93,619
14 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	8.1	200	1.62K	93,569
13 Jun 22	David Cunningham	Common stock $0.10 per value per share	Buy	Acquire P	No	No	8	1,000	8K	16,000
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.77	485	3.77K	93,369
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.82	48	375.36	92,884
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.79	90	701.1	92,836
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.81	462	3.61K	92,746
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.8	200	1.56K	92,284
13 Jun 22	David Scott Tomsche	Common stock $0.10 per value per share	Sale back to company	Acquire D	No	No	7.73	200	1.55K	92,084

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

ICCC institutional ownership history Ownership history

12.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	27	30	-10.0%
Opened positions	0	4	EXIT
Closed positions	3	2	+50.0%
Increased positions	9	5	+80.0%
Reduced positions	10	9	+11.1%

13F shares	Current	Prev Q	Change
Total value	22.68M	26.55M	-14.6%
Total shares	951.57K	924.34K	+2.9%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vanguard	204.33K	$1.97M	+22.2%
Renaissance Technologies	154.58K	$1.49M	-7.8%
Meristem Family Wealth	85.52K	$825K	0.0%
Shufro Rose & Co	82.05K	$792K	+358.1%
Bleichroeder	71.07K	$686K	+14.2%
MS Morgan Stanley	66.77K	$644K	+18.2%
Overbrook Management	45.88K	$443K	-39.2%
Perritt Capital Management	36.49K	$352K	-8.8%
Strategic Financial Services, Inc,	31K	$299K	+3.2%
Geode Capital Management	22.67K	$218K	+1.0%

Largest transactions	Shares	Bought/sold	Change
Shufro Rose & Co	82.05K	+64.14K	+358.1%
Aries Wealth Management	0	-44.1K	EXIT
Vanguard	204.33K	+37.08K	+22.2%
Overbrook Management	45.88K	-29.59K	-39.2%
Renaissance Technologies	154.58K	-13.04K	-7.8%
MS Morgan Stanley	66.77K	+10.3K	+18.2%
Bleichroeder	71.07K	+8.82K	+14.2%
Perritt Capital Management	36.49K	-3.51K	-8.8%
Essex Financial Services	11K	-1.72K	-13.5%
Captrust Financial Advisors	1.2K	+1K	+500.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Zoetis

Management Discussion

As detailed in Note 17, “Segment Information”, to the accompanying unaudited financial statements, we operate in two business segments. The Scours segment is dedicated to manufacturing and selling First Defense®, a product used to prevent scours in newborn calves, which is regulated by the USDA. The Mastitis segment is focused on developing and commercializing Re-Tain®, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the FDA.
Through both continued growth in sales of the First Defense® product line and a successful launch of Re-Tain® as soon as possible, and with a measured approach to expanding our customer-facing staff, it is our objective to increase our current annual level of total product sales of approximately $19.2 million for the year ended December 31, 2021 to approximately $23 million or more by the year ending December 31, 2023. As additional resources are dedicated to production, sales, marketing and technical services, our longer-term goal is to exceed $35 million of annual total product sales as soon as possible during the five-year period after the market launch of Re-Tain®.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: abstained, bacterial, birth, brand, breakthrough, broker, buffer, caught, comment, competitor, crop, crucial, differentiating, displace, divert, encouraged, erasing, escalate, feature, frame, fueled, guarantee, healthy, house, inconsistency, inconsistent, intent, internationally, landlord, leader, livestock, message, morbidity, mortality, norm, notify, pharma, plastic, polyclonal, profile, proven, proximity, recession, recessionary, reminded, research, resolve, resolved, satisfaction, Secondarily, shed, shell, substantive, therapeutic, thing, thirty, transform, true, type, unprotected, Urban, worthy

Removed: accept, batch, deductible, dumped, encountered, executing, extending, forgiven, immunize, implemented, involuntary, legacy, lifting, lunch, pace, Paycheck, payroll, peak, pivotal, PPP, preceding, purified, recurrence, reinspection, repeatability, school, senior, setback, slightly, swap, TD, temporarily, variance

From filing 10-Q 2022 Q2

Financial reports

View all